CoChat

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Open access
Wang, Rong, Yamada, Tadaaki, Kita, Kenji, Taniguchi, Hirokazu, Arai, Sachiko, Fukuda, Koji, Terashima, Minoru, Ishimura, Akihiko, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Ohtsubo, Koshiro, Yamashita, Kaname, Yamano, Tomoyoshi, Yoshimura, Akihiro, Takayama, Koichi, Kaira, Kyoichi, Taniguchi, Yoshihiko, Atagi, Shinji, Uehara, Hisanori, Hanayama, Rikinari, Matsumoto, Isao, Han, Xujun, Matsumoto, Kunio, Wang, Wei, Suzuki, Takeshi, Yano, Seiji · 2020 · Nature Communications
Cited by 115

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Drug tolerance is the basis for acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including osimertinib, through mechanisms that still remain unclear. Here, we show that while AXL-low expressing EGFR mutated lung cancer (EGFR mut-LC) cells are more sensitive to osimertinib than AXL-high expressing EGFR mut-LC cells, a small population emerge osimertinib tolerance. The tolerance is mediated by the increased expression and phosphorylation of insulin-like growth factor-1 receptor (IGF-1R), caused by the induction of its transcription factor FOXA1. IGF-1R maintains association with EGFR and adaptor proteins, including Gab1 and IRS1, in the presence of osimertinib and restores the survival signal. In AXL-low-expressing EGFR mut-LC cell-derived xenograft and patient-derived xenograft models, transient IGF-1R inhibition combined with continuous osimertinib treatment could eradicate tumors and prevent regrowth even after the cessation of osimertinib. These results indicate that optimal inhibition of tolerant signals combined with osimertinib may dramatically improve the outcome of EGFR mut-LC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18442-4

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 115

Metadata

Authors
Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., Takeuchi, S., Ohtsubo, K., Yamashita, K., Yamano, T., Yoshimura, A., Takayama, K., Kaira, K., Taniguchi, Y., Atagi, S., Uehara, H., Hanayama, R., Matsumoto, I., Han, X., Matsumoto, K., Wang, W., Suzuki, T., & Yano, S.
Venue
Nature Communications
Published
2020-09-14
Volume
11
Issue
1
Pages
4607-4607
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3086639494
Cited by
115
References
20
FWCI
8.87
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. https://app.cochat.ai/papers/10.1038/s41467-020-18442-4
The paper
Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., Takeuchi, S., Ohtsubo, K., Yamashita, K., Yamano, T., Yoshimura, A., Takayama, K., Kaira, K., Taniguchi, Y., Atagi, S., . . . Yano, S. (2020). Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications. https://doi.org/10.1038/s41467-020-18442-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.